Sugi Predict

Sugi Predict / Compounds / SCHEMBL25810667

SCHEMBL25810667

SCHEMBL25810667

CCOC(=O)c1cc2ccc(N3CCC4(CC3)CN(C(=O)OC(C)(C)C)C4)cc2s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACKR3 P25106 1/20 0.41
▸ CYP11B2 P19099 1/20 0.40
▸ ACACB O00763 3/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ SCD5 Q86SK9 1/20 0.39
▸ GPR183 P32249 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ CHRNA7 P36544 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ PTPN2 P17706 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30492841 0.92 ACKR3 (0.40) ACKR3CYP2C9NAMPTGPR119MAPT
SCHEMBL31025966 0.92 ACKR3 (0.40) ACKR3CYP2C9NAMPTGPR119MAPT
SCHEMBL25810669 0.89 SCD5 (0.43) ACKR3CYP11B2ACACBCYP2C9NAMPT
SCHEMBL25260268 0.88 MAPT (0.49) ACKR3CYP2C9NAMPTGPR119MAPT
SCHEMBL30492859 0.88 MAPT (0.49) ACKR3CYP2C9NAMPTGPR119MAPT
SCHEMBL30492874 0.83 CHRNA7 (0.43) MAPTALDH1A1LMNACHRNA7PTPN2
SCHEMBL25810428 0.83 CHRNA7 (0.43) MAPTALDH1A1LMNACHRNA7PTPN2
SCHEMBL30492882 0.82 CHRNA7 (0.40) MAPTLMNACHRNA7PTPN2MAPK1
SCHEMBL31025994 0.82 CHRNA7 (0.43) MAPTALDH1A1LMNACHRNA7PTPN2
SCHEMBL25298855 0.82 CHRNA7 (0.43) MAPTALDH1A1LMNACHRNA7PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) 2025-03-06 — — US disclosed
WO-2025002040-A1 CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海京新生物医药有限公司 2025-01-02 — — WO disclosed
EP-4458824-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR Shanghai Jingxin Biomedical Co., Ltd. (CN) 2024-11-06 — — EP disclosed
CN-118488951-A Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation 上海京新生物医药有限公司 2024-08-13 — — CN disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 — — WO disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR HTT, PARK7, FUS ACKR3 3819/4885CYP11B2 4672/4885ACACB 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.